AZD7325
Phase 2Small molecule
AstraZenecaAZD7325 is one of 144 small molecule programs targeting Cognition. It is currently in Phase 2.
4
Indications
15
Total Trials
0
Active Trials
143
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
191 competitors in Cognition
#DrugCompanyPhaseTrials
1AZD7325
AstraZenecaPhase 2
Activella
Eli LillyPreclinical
Estrace
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Ozempic
Novo NordiskPreclinical
Galvus
NovartisPreclinical
Depo-Provera
PfizerPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Marinol
Alnylam PharmaceuticalsPreclinical
Veramyst
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Generalized Anxiety Disorder2 trials
Central Nervous System1 trial
Female1 trial
5 more indications
Fragile X Syndrome1 trial
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
Completed·—·Phase 1·NCT03140813·15 enrolled
Autism Spectrum Disorder1 trial
Intravenous1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD7325. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company